4SC - Resminostat and RESMAIN Study Update - 4SC AG
The RESMAIN study, evaluating resminostat for advanced-stage CTCL maintenance, continues without protocol changes after a positive DSMB safety review. Enrollment increased to 190 patients to expedite unblinding, with results expected by mid-2021. Yakult Honsha discontinued a Phase II study in Japan, with no financial impact on 4SC.
Reference News
4SC - Resminostat and RESMAIN Study Update - 4SC AG
The RESMAIN study, evaluating resminostat for advanced-stage CTCL maintenance, continues without protocol changes after a positive DSMB safety review. Enrollment increased to 190 patients to expedite unblinding, with results expected by mid-2021. Yakult Honsha discontinued a Phase II study in Japan, with no financial impact on 4SC.